A non-myeloablative regimen with minimal non relapse mortality for allografting patients with Hodgkin's disease

被引：0
|
作者：
Kottaridis, P
Milligan, D
Chopra, R
Craddock, C
Mahendra, P
Hunter, A
Marsh, J
Chakraverty, R
Mills, A
Kyriakou, C
McKeag, N
Hale, G
Waldmann, H
Linch, D
Goldstone, A
Mackinnon, S
机构：
来源：
BONE MARROW TRANSPLANTATION | 2001年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [31] Allogeneic Hematopoietic Stem Cell (HSC) grafting and non-myeloablative regimen in patients with hematological malignancies.
    Hansz, J
    Gozdzik, J
    Gil, L
    Drozdowska, D
    Kozlowska-Skrzypczak, M
    Sawinski, K
    BONE MARROW TRANSPLANTATION, 2001, 27 : S289 - S289
  • [32] Pentostatin based non-myeloablative conditioning regimen in patients with high-risk hematologic malignancy.
    Bayer, RL
    Feldman, EJ
    Coleman, M
    Roboz, G
    Leonard, J
    Michaeli, J
    Schuster, MW
    BLOOD, 2000, 96 (11) : 327B - 327B
  • [33] MINIMAL RESIDUAL DISEASE IN NON HODGKIN'S LYMPHOMAS
    Galimberti, S.
    HAEMATOLOGICA, 2018, 103 : S6 - S7
  • [34] Longer follow-up confirms a low relapse rate after non-myeloablative allogeneic transplantation (NMT) for Non-Hodgkin's lymphoma (NHL), including patients with PET or gallium-avid disease.
    Khouri, IF
    Saliba, RM
    Lee, MS
    Okoroji, GJ
    Fayad, L
    Maadani, F
    Hosing, C
    Samuels, B
    Giralt, S
    de Lima, M
    Pro, B
    Younes, A
    McLaughlin, P
    Kwak, L
    Champlin, RE
    BLOOD, 2005, 106 (11) : 17A - 18A
  • [35] Reduction of treatment-related mortality in non-myeloablative allogeneic transplantation
    Van Hoef, MEHM
    BONE MARROW TRANSPLANTATION, 2006, 37 : S324 - S324
  • [36] Remission status and histology predict long-term results of non-myeloablative transplantation in non-Hodgkin's lymphomas
    Gayoso, J.
    Balsalobre, P.
    Tomas, J. F.
    de la Serna, J.
    Serrano, D.
    Carrion, R.
    Buno, I.
    Gomez-Pineda, A.
    Diez-Martin, J. L.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S210 - S210
  • [37] Tandem Autologous/Non-Myeloablative Allogeneic Transplantation for High Risk Non-Hodgkin Lymphoma (NHL)
    Fakhri, Bita
    Cashen, Amanda
    Comer, Holly
    Abboud, Camille
    Westervelt, Peter
    DiPersio, John E.
    Stockerl-Goldstein, Keith
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S300 - S300
  • [38] Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma
    Bruno, Benedetto
    Storer, Barry
    Patriarca, Francesca
    Rotta, Marcello
    Sorasio, Roberto
    Allione, Bernardino
    Carnevale-Schianca, Fabrizio
    Giaccone, Luisa
    Festuccia, Moreno
    Brunello, Lucia
    Omede, Paola
    Ferrando, Federica
    Bringlien, Sara
    Aglietta, Massimo
    Levis, Alessandro
    Mordini, Nicola
    Gallamini, Andrea
    Palumbo, Antonio
    Fanin, Renato
    Storb, Rainer
    Gooley, Ted
    Boccadoro, Mario
    BLOOD, 2010, 116 (21) : 233 - 233
  • [39] Low-dose TBI-based non-myeloablative allografting in newly diagnosed multiple myeloma
    Bruno, B
    Patriarca, F
    Rotta, M
    Maloney, D
    Mordini, N
    Casini, M
    Rambaldi, A
    Carnevale-Schianca, F
    Allione, B
    Soligo, D
    Bavaro, P
    De Fabritiis, P
    Giaccone, L
    Aitoro, G
    Corradini, P
    Busca, A
    Fanin, R
    Gallamini, A
    Coser, P
    Levis, A
    Aglietta, M
    Pogliani, E
    Falda, M
    Massaia, M
    Palumbo, A
    Sandmaier, B
    Storb, R
    Boccadoro, M
    BONE MARROW TRANSPLANTATION, 2004, 33 : S9 - S10
  • [40] Immunosuppressive non-myeloablative allografting has reduced toxicity also in highly pretreated hematological and non-hematological neoplasia.
    Carella, AM
    Corsetti, MT
    Beltrami, G
    Greco, MM
    Lerma, E
    Scalzulli, PR
    Savino, L
    Ferrara, R
    Centra, M
    Giorgio, D
    Carella, AM
    BLOOD, 2002, 100 (11) : 623A - 624A
12345